C John

452 total citations
21 papers, 160 citations indexed

About

C John is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, C John has authored 21 papers receiving a total of 160 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 15 papers in Epidemiology and 3 papers in Infectious Diseases. Recurrent topics in C John's work include Hepatitis C virus research (18 papers), Hepatitis B Virus Studies (11 papers) and Liver Disease Diagnosis and Treatment (8 papers). C John is often cited by papers focused on Hepatitis C virus research (18 papers), Hepatitis B Virus Studies (11 papers) and Liver Disease Diagnosis and Treatment (8 papers). C John collaborates with scholars based in Germany, Switzerland and United States. C John's co-authors include R Heyne, D. Hueppe, Stefan Mauss, Axel Baumgarten, U. Alshüth, Nektarios Dikopoulos, Bernd Moeller, T. Witthoeft, G Teuber and William Samuel and has published in prestigious journals such as Journal of Hepatology, Journal of Viral Hepatitis and European journal of medical research.

In The Last Decade

C John

20 papers receiving 159 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C John Germany 7 136 131 25 15 12 21 160
A. Yosry Egypt 7 245 1.8× 220 1.7× 15 0.6× 20 1.3× 14 1.2× 19 268
A. Osinusi Germany 5 137 1.0× 113 0.9× 27 1.1× 24 1.6× 3 0.3× 15 146
H. Fontaine France 7 275 2.0× 265 2.0× 17 0.7× 35 2.3× 4 0.3× 22 286
Alison Uriel United Kingdom 7 172 1.3× 150 1.1× 10 0.4× 46 3.1× 6 0.5× 10 211
Aimilia Karampatou Italy 3 115 0.8× 106 0.8× 18 0.7× 10 0.7× 6 0.5× 3 154
Carola Mix Germany 6 303 2.2× 288 2.2× 20 0.8× 37 2.5× 13 320
Sergio Veloso Spain 7 122 0.9× 121 0.9× 12 0.5× 73 4.9× 5 0.4× 10 199
Santos del Campo Spain 7 95 0.7× 87 0.7× 10 0.4× 14 0.9× 21 133
Ritsuzo Kozuka Japan 9 138 1.0× 141 1.1× 8 0.3× 12 0.8× 3 0.3× 32 161
P. Mélin France 8 315 2.3× 282 2.2× 15 0.6× 65 4.3× 7 0.6× 20 335

Countries citing papers authored by C John

Since Specialization
Citations

This map shows the geographic impact of C John's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C John with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C John more than expected).

Fields of papers citing papers by C John

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C John. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C John. The network helps show where C John may publish in the future.

Co-authorship network of co-authors of C John

This figure shows the co-authorship network connecting the top 25 collaborators of C John. A scholar is included among the top collaborators of C John based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C John. C John is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stoehr, Albrecht, Hartwig Klinker, G Teuber, et al.. (2020). Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease - Data from the German Hepatitis C-Registry (DHC-R). Zeitschrift für Gastroenterologie. 2 indexed citations
2.
Christensen, Steen Bach, Albrecht Stoehr, Markus Cornberg, et al.. (2019). High real-world effectiveness of elbasvir/grazoprevir (EBR/GZR) in PWID on opioid substitution therapy with HCV genotype 1 (GT1) infection: results from the German Hepatitis C Registry (DHC-R). Zeitschrift für Gastroenterologie. 1 indexed citations
3.
Tacke, Frank, Rolf W. Günther, Peter Buggisch, et al.. (2016). Treatment of HCV Genotype 2 with Sofosbuvir and Ribavirin Results in Low SVR Rates ina Real World Cohort (German Hepatitis C-Registry, DHC-R). Journal of Hepatology. 64(2). S767–S767. 3 indexed citations
4.
John, C, et al.. (2015). Neutrophil to Lymphocyte Ratio in Sickle Cell Anaemia Patients with Nephropathy. British Journal of Medicine and Medical Research. 10(11). 1–6. 2 indexed citations
5.
Samuel, William, et al.. (2015). In vitro activity and in vivo efficacy of a combination therapy of diminazene and chloroquine against murine visceral leishmaniasis. Journal of Biomedical Research. 29(3). 214–214. 17 indexed citations
6.
Petersen, J., R Heyne, JF Schlaak, et al.. (2014). O122 EFFECTIVENESS OF TENOFOVIR DF FOR CHRONIC HEPATITIS B IN FIELD PRACTICE – 3 YEAR FINAL RESULTS FROM THE PROSPECTIVE GERMAN MULTICENTER NON-INTERVENTIONAL STUDY. Journal of Hepatology. 60(1). S51–S51. 3 indexed citations
7.
Stahmeyer, Jona T., S. Rossol, Ahmed Abdelfattah, et al.. (2014). P1147 OUTCOMES AND COSTS OF TREATING HEPATITIS C WITH PROTEASE INHIBITORS: RESULTS FROM A MULTI-CENTRE STUDY. Journal of Hepatology. 60(1). S464–S465. 2 indexed citations
8.
Petersen, John Asger, R Heyne, JF Schlaak, et al.. (2013). 768 EFFECTIVENESS OF TENOFOVIR FOR CHRONIC HEPATITIS B IN FIELD PRACTICE – 2 YEAR INTERIM RESULTS FROM THE PROSPECTIVE GERMAN MULTICENTER NON-INTERVENTIONAL STUDY (GEMINIS). Journal of Hepatology. 58. S313–S313. 5 indexed citations
9.
10.
11.
Hueppe, D., Stefan Mauss, Andreas Schober, et al.. (2013). Prädiktive Baseline Faktoren bei Patienten mit Zirrhose für den Therapieerfolg einer dualen Therapie mit Peginterferon alfa-2a (PEG) plus Ribavirin (RBV), was zählt?. Zeitschrift für Gastroenterologie. 51(8). 1 indexed citations
12.
13.
Mauss, Stefan, F. Berger, Andreas Schober, et al.. (2012). Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome. Journal of Viral Hepatitis. 20(4). e72–7. 16 indexed citations
14.
Vogel, M., Golo Ahlenstiel, Thomas A. Lutz, et al.. (2010). The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals. European journal of medical research. 15(3). 102–11. 8 indexed citations
15.
Hueppe, D., C John, R Heyne, et al.. (2010). Estimating the likelihood of sustained virological response in chronic hepatitis C therapy. Journal of Viral Hepatitis. 18(4). e81–90. 19 indexed citations
16.
Witthoeft, T., D. Hueppe, C John, et al.. (2010). Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study. Journal of Viral Hepatitis. 17(7). 459–68. 23 indexed citations
17.
Jaeckel, Elmar, E Zehnter, C John, et al.. (2010). 266 CLINICAL MARKERS OF THE METABOLIC SYNDROME ARE ASSOCIATED WITH HCV GENOTYPE 1 INFECTION AND ARE STRONG NEGATIVE PREDICTORS OF EARLY VIROLOGICAL RESPONSE. Journal of Hepatology. 52. S112–S112. 2 indexed citations
18.
Hueppe, D., C John, Urs Meyer, et al.. (2008). 811 ESTIMATING THE LIKELIHOOD OF SUSTAINED VIROLOGICAL RESPONSE IN CHRONIC HEPATITIS C (CHC) THERAPY. Journal of Hepatology. 48. S303–S304.
19.
Hüppe, D, E Zehnter, Tracey Lutz, et al.. (2008). Epidemiologie der chronischen Hepatitis C in Deutschland - Eine Analyse von 10 326 Hepatitis-C-Virus-Infizierten aus Schwerpunktpraxen und -ambulanzen. Zeitschrift für Gastroenterologie. 46(1). 34–44. 36 indexed citations
20.
Rockstroh, Jürgen K., M. Vogel, Gerd Klausen, et al.. (2007). [636] THE INFLUENCE OF NUCLEOSIDE FREE HAART ON THE TREATMENT OF CHRONIC HEPATITIS C WITH PEGYLATED INTERFERON/RIBAVIRIN COMBINATION TREATMENT. Journal of Hepatology. 46. S240–S240. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. Yosry Breakdown of academic impact, for papers by A. Osinusi Breakdown of academic impact, for papers by H. Fontaine Breakdown of academic impact, for papers by Alison Uriel Breakdown of academic impact, for papers by Aimilia Karampatou Breakdown of academic impact, for papers by Carola Mix Breakdown of academic impact, for papers by Sergio Veloso Breakdown of academic impact, for papers by Santos del Campo Breakdown of academic impact, for papers by Ritsuzo Kozuka Breakdown of academic impact, for papers by P. Mélin
Rankless by CCL
2026